Serum albumin is strongly associated with eryhtropoietin sensitivity in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 98-104

  Agarwal, Rajiv ^a   Davis, Joyce L ^a   Smith, Linda ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN; ERYTHROPOIETIN; HEMOGLOBIN; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; BIOLOGICAL MARKERS; CHEMOKINE CCL2; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LEUKOCYTE COUNT; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 38749123526     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03330807     Document Type: Article

References (29)

1. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
2. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
3. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005
4. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, DeOreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64: 1514-1521, 2003
5. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: S11-S145, 2006
6. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis, patients. Am J Kidney Dis 29: 565-568, 1997
7. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72, 1999
8. Locatelli F, Andrulli S, Memoli B, Maffei C, Del VL, Aterini S, De SW, Mandalari A, Brunori G, Amato M, Cianciaruso B, Zoccali C: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 21: 991-998, 2006
9. Portoles J, Lopez-Gomez JM, Aljama P: Anemia management and treatment response in patients on hemodialysis: The MAR study. J Nephrol 19: 352-360, 2006
10. Agarwal R, Chase SD: Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 775: 121-126, 2002
11. Agarwal R: Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69: 1259-1263, 2006
12. Singer JD: Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behavior Stat 24: 323-355, 1998
13. Singer JD, Willett JB: Applied longitudinal data analysis modeling change and event occurrence. Oxford, Oxford University Press, 2003
14. Fishbane S: Iron supplementation in renal anemia. Semin Nephrol 26: 319-324, 2006
15. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000
16. Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 55: 1891-1898, 1999
17. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M: Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol 2: 688-693, 2007
18. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16: 1416-1423, 2001
19. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52: 217-222, 1997
20. Singh AK, Coyne DW, Shapiro W, Rizkala AR: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71: 1163-1171, 2007
21. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975-984, 2007
22. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999
23. Steinman TI: Serum albumin: Its significance in patients with ESRD. Semin Dial 13: 404-408, 2000
24. Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32: S118-S125, 1998
25. Bindra K, Berry C, Rogers J, Stewart N, Watts M, Christie J, Cobbe SM, Eteiba H: Abnormal haemoglobin levels in acute coronary syndromes. QJM 99: 851-862, 2006
26. Sirken G, Kung SC, Raja R: Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 49: 422-425, 2003
27. Alfrey CP, Fishbane S: Implications of neocytolysis for optimal management of anaernia in chronic kidney disease. Nephron Clin Pract 106: c149-c156, 2007
28. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
29. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004